Nevertheless, clinical trials and studies to date have not confirmed preclinical evidence, with patients harboring EGFR mutations having worse outcomes than patients with EGFR wt NSCLC on anti-PD-(L)1 ICIs [155,156,157]. Here, EGFR is linked to non-small cell lung carcinoma.